Elliott Sigal Overview
- Investor Type
-
Angel
- Status
-
Active
- Professionals
-
1

- Investments
-
3
- Exits
-
3

Elliott Sigal General Information
Description
Dr. Elliott Sigal serves as Board Member at Vir. Mr. Sigal served as Venture Partner and Senior Advisor at New Enterprise Associates. He serves as Board Member at Affinia Therapeutics. He serves as a Board Member and Non-Executive Director at Adaptimmune Therapeutics. He served as a Board Member at Spark Therapeutics. He serves as Board Member at Tessera Therapeutics. He joined NEA in 2014. He also served as a Board Member & Member of Nominating, Corporate Governance Committee at Surface Oncology. He is a former Executive Vice President and Director of Bristol-Myers Squibb and served as Chief Scientific Officer and President of R&D for Bristol-Myers Squibb from 2004 until 2013. He was the principal architect of the successful Biopharma Transformation Strategy of the company. He has been instrumental in increasing R&D productivity, developing the company's strategy in biologics and acquiring external innovation in Bristol's String of Pearls initiative. Under his leadership, fourteen new medicines have come to market including Abilify (Schizophrenia, Bipolar Disorder), Reyataz (HIV/AIDS), Erbitux (Colon Cancer), Baraclude (Hepatitis B), Orencia (Rheumatoid Arthritis), Sprycel (Leukemia), Atripla (HIV/AIDS), Ixempra (Breast Cancer), Onglyza and Kombiglyze (Diabetes), Nulojix (Transplantation), Eliquis (Anticoagulant), Yervoy (Melanoma), and Forxiga (Diabetes). Among his accomplishments in various therapeutic areas was building BMS research into a leadership position in the promising area of immuno-oncology. In 2012, Mr. Sigal was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence. Mr. Sigal currently serves as a senior advisor to the healthcare team of New Enterprise Associates and also consults for select biotechnology companies. Mr. Sigal received his M.D. from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco (UCSF). Prior to medical school, he studied Engineering at Purdue University, where he received a B.S., M.S., and Ph.D. Mr. Sigal serves as a member of the Board of Directors for Mead Johnson Nutrition Company and the Melanoma Research Alliance.
Business Details
Investor Status
Primary Investor Type
Corporate Office
- Princeton, NJ
- United States
Elliott Sigal Investments (3)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Mersana Therapeutics | 02-Mar-2015 | Later Stage VC | Biotechnology | Generating Revenue/Not Profitable | ||
Surface Oncology | 21-Nov-2014 | Drug Discovery | Generating Revenue/Not Profitable | |||
Adaptimmune Therapeutics | 19-Sep-2014 | Pharmaceuticals | Generating Revenue/Not Profitable |
Elliott Sigal Exits (3)
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
Surface Oncology | 19-Apr-2018 | IPO | |
Mersana Therapeutics | 28-Jun-2017 | ||
Adaptimmune Therapeutics | 06-May-2015 |
Elliott Sigal Investments by Industry, Year, and Region
Elliott Sigal FAQs
-
Who is Elliott Sigal?
Elliott Sigal is an angel Investor who has made 3 investments.
-
What kind of investor is Elliott Sigal?
Elliott Sigal is an angel investor.
-
What does Elliott Sigal do?
As an angel investor, Elliott Sigal invests personal money into promising companies, typically in exchange for equity.
-
How many board seats does Elliott Sigal hold?
Elliott Sigal holds 2 board seats including Tessera Therapeutics and Vir.
-
What has Elliott Sigal invested in?
Elliott Sigal has made numerous investments in companies like Mersana Therapeutics, Surface Oncology, and Adaptimmune Therapeutics within the Biotechnology, Drug Discovery, and Pharmaceuticals industries.
-
What has Elliott Sigal invested in recently?
Elliott Sigal's latest investment was on 02-Mar-2015 in Mersana Therapeutics, a company within the Biotechnology industry.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »